Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (airflow-3)

HIGHLIGHTS

• who: Dirk-Jan Slebos from the Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Hanzeplein, RB, Groningen, The Netherlands have published the research: Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3), in the Journal: (JOURNAL)
• what: To assess the primary objective, the primary endpoint is a comparison of time-to-first event for moderate or severe COPD exacerbations between the active treatment arm and the sham control arm based on . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.